Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma
Background. Endometrial stromal sarcomas (ESS) are a subtype of gynaecological sarcomas characterized by the overexpression of hormone receptors. Hormone treatment is widely used in ESS but primary or acquired resistance is common. The mammalian target of rapamycin (mTOR) pathway has been suggested...
Saved in:
Main Authors: | J. Martin-Liberal, C. Benson, C. Messiou, C. Fisher, I. Judson |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Case Reports in Medicine |
Online Access: | http://dx.doi.org/10.1155/2014/612496 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence
by: Goran B. Klintmalm, et al.
Published: (2014-01-01) -
A Decade of Experience Using mTor Inhibitors in Liver Transplantation
by: Jeffrey Campsen, et al.
Published: (2011-01-01) -
Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer
by: Athanasia Pavlidou, et al.
Published: (2014-01-01) -
Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors
by: Gianluigi Zaza, et al.
Published: (2013-01-01) -
Laparoscopic Sentinel Node Mapping with Surgical Staging following Hysteroscopic Endometrial Resection in Endometrial Stromal Sarcoma
by: Phornsawan Wasinghon, et al.
Published: (2020-08-01)